Bafetinib. Dual BCR/ABL and Lyn tyrosine kinase inhibitor treatment of chronic myeloid leukemia

Drugs of the Future

Volumn 34, Issue 4, 2009, Pages 261-269

  Takeuchi, M ^a   Kimura, S ^a   Ashihara, E ^a   Maekawa, T ^a  

^a KYOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3 DIMETHYLAMINO 1 PYRROLIDINYLMETHYL) 3 TRIFLUOROMETHYL N [4 METHYL 3 [[4 (5 PYRIMIDINYL) 2 PYRIMIDINYL]AMINO]PHENYL]BENZAMIDE; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BCR ABL PROTEIN; BOSUTINIB; DASATINIB; IMATINIB; NILOTINIB; PROTEIN KINASE LYN; TRIACYLGLYCEROL LIPASE;

ADVANCED CANCER; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUTOPHOSPHORYLATION; BLOOD TOXICITY; CANCER INHIBITION; CANCER PATIENT; CANCER RESISTANCE; CANCER STAGING; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM; CHRONIC MYELOID LEUKEMIA; DIARRHEA; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG POTENCY; DRUG SELECTIVITY; DRUG TOLERABILITY; HUMAN; NONHUMAN; PERICARDIAL EFFUSION; PERIPHERAL EDEMA; PLEURA EFFUSION; SIDE EFFECT; TREATMENT RESPONSE; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; WILD TYPE;

EID: 76649127373     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2009.034.04.1338544     Document Type: Article

References (37)

1. Asaki, T., Sugiyama, Y., Hamamoto, T., Higashioka, M., Umehara, M., Naito, H., Niwa, T. Design and synthesis of 3-substituted benzamide derivatives as Bcr-Abl kinase inhibitors. Bioorg Med Chem Lett 2006, 16(5): 1421-5.
2. Asaki, T., Sugiyama, Y., Segawa, J. (Nippon Shinyaku Co., Ltd.). Amide derivative and medicine. EP 1702917, US 2008293940, WO 2005063709.
3. Rowley, J.D. A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Gimsa staining. Nature 1973, 243(5405): 290-3.
4. Sawyers, C.L. Chronic myeloid leukemia. N Engl J Med 1999, 340(17): 1330-40.
5. Buchdunger, E., Zimmermann, J., Mett, H., Meyer, T., Müller, M., Druker, B.J., Lydon, N.B. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 1996, 56(1): 100-4.
6. O'Brien, S.G., Guilhot, F., Larson, R.A. et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003, 348(11): 994-1004.
7. Goldman, J.M., Melo, J.V. Chronic myeloid leukemia - Advances in biologyand new approaches to treatment. N Engl J Med 2003, 348(15): 1451-64.
8. Druker, B.J. Chronic myeloid leukemia in the imatinib era. Semin Hematol 2003, 40(2, Suppl. 2): 1-3.
9. Druker, B.J., Sawyers, C.L., Kantarjian, H. et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001, 344(14): 1038-42.
10. Ottmann, O.G., Druker, B.J., Sawyers, C.L. et al. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood 2002, 100(6): 1965-71.
11. Gorre, M.E., Mohammed, M., Ellwood, K. et al. Clinical resistance to STI571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001, 293(5531): 876-80.
12. + acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation. Blood 2002, 99(5): 1860-2.
13. Nardi, V., Azam, M., Daley, G.Q. Mechanisms and implications of imatinib resistance mutations in BCR-ABL. Curr Opin Hematol 2004, 11(1): 35-43.
14. Deininger, M., Buchdunger, E., Druker, B.J. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 2005, 105(7): 2640-53.
15. Hegedus, T., Orfi, L., Seprodi, A., Váradi, A., Sarkadi, B., Kéri, G. Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1. Biochim Biophys Acta 2002, 1587(2-3): 318-25.
16. Donato, N.J., Wu, J.Y., Stapley, J., Gallick, G., Lin, H., Arlinghaus, R., Talpaz, M. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 2003, 101(2): 690-8.
17. Dai, Y., Rahmani, M., Corey, S.J., Dent, P., Grant, S. A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2. J Biol Chem 2004, 279(33): 34227-39.
18. Ptasznik, A., Nakata, Y., Kalota, A., Emerson, S.G., Gewirtz, A.M. Short interfering RNA (siRNA) targeting the Lyn kinase induces apoptosis in primary, and drug-resistant, BCR-ABL1(+) leukemia cells. Nat Med 2004, 10(11): 1187-9.
19. Cortes, J., Giles, F., O'Brien, S. et al. Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-α. Blood 2003, 102(1): 83-6.
20. Kantarjian, H., Talpaz, M., O'Brien, S. et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood 2004, 103(8): 2873-8.
21. O'Brien, S., Giles, F., Talpaz, M. et al. Results of triple therapy with interfer-on-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase. Cancer 2003, 98(5): 888-93.
22. Shah, N.P., Tran, C., Lee, F.Y., Chen, P., Norris, D., Sawyers, C.L. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004, 305(5682): 399-401.
23. Weisberg, E., Manley, P.W., Breitenstein, W. et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005, 7(2): 129-41.
24. Golas, J.M., Arndt, K., Etienne, C. et al. SKI-606, a 4-anilino-3-quino-linecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. Cancer Res 2003, 63(2): 375-81.
25. Kimura, S., Naito, H., Segawa, H. et al. NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia. Blood 2005, 106(12): 3948-54.
26. Nagar, B., Bornmann.W.G., Pellicena, P. et al. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res 2002, 62(15): 4236-43.
27. Kimura, S., Niwa, T., Hirabayashi, K., Maekawa, T. Development of NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor. Cancer Chemother Pharm 2006, 58(Suppl. 7): 55-61.
28. Horio, T., Hamasaki, T., Inoue, T. et al. Structural factors contributing to the Abl/Lyn dual inhibitory activity of 3-substituted benzamide derivatives. Bioorg Med Chem Lett 2007, 17(10): 2712-7.
29. Melo, J.V., Chuah, C. Resistance to imatinib mesylate in chronic myeloid leukaemia. Cancer Lett 2007, 249(2): 121-32.
30. Branford, S. Chronic myeloid leukemia: Molecular monitoring in clinical practice. Hematol Am Soc Hematol Educ Program 2007, 376-83.
31. Naito, H., Kimura, S., Nakaya, Y. et al. In vivo antiproliferative effect of NS-187, a dual Bcr-Abl/Lyn tyrosine kinase inhibitor, on leukemic cells harbouring Abl kinase domain mutations. Leuk Res 2006, 30(11): 1443-6.
32. Kuroda, J., Kimura, S., Strasser, A. et al. Apoptosis-based dual molecular targeting by INNO-406, a second generation Bcr-Abl inhibitor, and ABT-737, an inhibitor of anti-apoptotic Bcl-2 proteins, against Bcr-Abl-positive leukemia. Cell Death Diff 2007, 14(9): 1667-77.
33. Kamitsuji, Y., Kuroda, J., Kimura, S. et al. The Bcr-Abl kinase inhibitor INNO-406 induces autophagy and different modes of cell death execution in Bcr-Abl leukemias. Cell Death Diff 2008, 15(11): 1712-22.
34. Deguchi, Y., Kimura, S., Ashihara, E., Niwa, T., Hodohara, K., Fujiyama, Y., Maekawa, T. Comparison of imatinib, dasatinib, nilotinib and INNO-406 in imatinib-resistant cell lines. Leuk Res 2008, 32(6): 980-3.
35. Morinaga, K., Yamauchi, T., Kimura, S., Maekawa, T., Ueda, T. Overcoming imatinib resistance using Src inhibitor CGP76030, Abl inhibitor nilotinib and Abl/Lyn inhibitor INNO-406 in newly established K562 variants with BCR-ABL gene amplification. Int J Cancer 2008, 122(11): 2621-7.
36. + leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity. Blood 2007, 109(1): 306-14.
37. Kantarjian, H.M., Cortes, J., Le Coutre, P. et al. A Phase I study of INNO-406 in patients with advanced Philadelphia (Ph plus) chromosome-positive leukemias who are resistant or intolerant to imatinib and second generation tyrosine kinase inhibitors. Blood 2007,110:144A.